Mogamulizumab-kpkc

(Poteligeo®)

Mogamulizumab-kpkc

Drug updated on 11/16/2023

Dosage FormInjection (intravenous: 20 mg/5 mL (4 mg/mL))
Drug ClassCC chemokine receptor type 4 (CCR4)- directed monoclonal antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.